Deutsche Bank views Danaher's (DHR) acquisition of Pall Corp. (PLL) as expensive and thinks the company's cost synergy expectations are aggressive. The firm adds that it doesn't fully comprehend the rationale of Danaher's plan to separate into two companies. Deutsche raised its price target for Danaher to $87 from $83 and keeps a Hold rating on the name.

Unusual total active option classes on open include: Steel Dynamics (STLD), Gildan Activewear (GIL), Danaher (DHR), Altimeter Growth (GRAB), Childrens Place (PLCE), ASML (ASML), US Bancorp (USB), iShares Barclays 7 to 10 Year Treasury Bond Fund (IEF), AMC Entertainment (AMC), and Abbott (ABT).

HSBC analyst Rajesh Kumar upgraded Danaher to Buy from Hold with a price target of $280, up from $250. HSBC's supply chain analysis suggests the de-stocking effects as well as order books might be on a recovery path for the life sciences tools sector, the analyst tells investors in a research note. The firm also believes the "geopolitical divide" of biotech funding around the U.S. Biosecure Act might result in a better pricing environment for outsourcers, potentially supporting incremental margins and multiples. It upgrades Danaher as a "quality proxy for the Biotech funding recovery."